Kymera Therapeutics (KYMR) FCF Margin (2019 - 2026)
Kymera Therapeutics' (KYMR) quarterly FCF Margin came in at 259.78% in Q1 2026, up 10048.0% year-on-year from N/an in Q1 2025, and up 89.73% on a QoQ basis from 2528.5% in Q4 2025.
Kymera Therapeutics (KYMR) FCF Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of FCF Margin data on file, last reported at 259.78% in Q1 2026.
- On a quarterly basis, FCF Margin rose 10048.0% year-over-year to 259.78% in Q1 2026; TTM through Mar 2026 was 485.11%, a 7760.0% decrease from a year earlier, with the FY2025 full-year figure at 612.21%, down 17174.0% from the prior year.
- FCF Margin for Q1 2026 stood at 259.78%, up from 2528.5% in the prior quarter.
- Over the last five years, FCF Margin for KYMR reached as high as 18.7% in Q4 2023 and fell as low as 2528.5% in Q4 2025.
- Historically, FCF Margin has averaged 587.72% across 5 years, with a median of 371.85% in 2022.
- On a YoY basis, FCF Margin climbed as much as 34919 bps in 2025 and fell as far as 168025 bps in 2025.
- Year by year, FCF Margin stood at 235.89% in 2022, then soared by 108 bps to 18.7% in 2023, then slumped by 4636 bps to 848.26% in 2024, then slumped by 198 bps to 2528.5% in 2025, then soared by 90 bps to 259.78% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 259.78% in Q1 2026, 2528.5% in Q4 2025, and 987.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.11 Bn | - | -259.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -259.78% |
| Dec 31, 2025 | -2,528.50% |
| Sep 30, 2025 | -987.37% |
| Jun 30, 2025 | -527.88% |
| Mar 31, 2025 | -360.26% |
| Dec 31, 2024 | -848.26% |
| Sep 30, 2024 | -1,336.57% |
| Jun 30, 2024 | -185.67% |
| Mar 31, 2024 | -456.82% |
| Dec 31, 2023 | 18.70% |
| Sep 30, 2023 | -356.81% |
| Jun 30, 2023 | -278.71% |
| Mar 31, 2023 | -506.83% |
| Dec 31, 2022 | -235.89% |
| Sep 30, 2022 | -371.85% |
| Jun 30, 2022 | -344.97% |
| Mar 31, 2022 | -423.79% |
| Dec 31, 2021 | -256.94% |
| Sep 30, 2021 | -184.73% |
| Jun 30, 2021 | -168.14% |